The link between economy-wide prosperity and health is increasingly recognized [ 1 ]. Compelling evidence from studies [ 2 , 3 ] and the World Health Organization (WHO) report [ 4 ] highlight the reciprocal relationship between economic development …
Authors:
Askal Ayalew Ali, Amit Kulkarni, Sandipan Bhattacharjee, Vakaramoko Diaby
Skin cancer is one of the most common cancers worldwide, with basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and melanoma being the most common types. BCC and SCC are called keratinocyte carcinoma (KC) together and account for 99% of …
Authors:
Annick Meertens, Laura Van Coile, Tijs Van Iseghem, Lieve Brochez, Nick Verhaeghe, Isabelle Hoorens
Open Access
15-05-2024 | Original Research Article
The EQ-5D is one of the most widely used instruments to measure health-related quality of life (HRQoL) in adults [ 1 ]. The EQ-5D-Y was developed to measure HRQoL in children and young people aged 4–15 years, and aims to facilitate the economic …
Authors:
Mina Bahrampour, Nancy Devlin, Renee Jones, Kim Dalziel, Brendan Mulhern, On behalf of the QUOKKA (Quality of Life in Kids: Key Evidence for Decision Makers in Australia) Team
Many countries have developed some form of ‘value-based pricing (VBP)’ to establish the prices of innovative health products. VBP avoids the use of a ‘cost-based’ approach that would attempt to calculate prices to cover the costs of production …
Author:
Salah Ghabri
Open Access
10-05-2024 | COVID-19 | Systematic Review
In a world where resources are limited and healthcare costs keep rising, health technology assessment (HTA) becomes crucial to making informed decisions about the allocation of resources for health-related interventions. Even (and perhaps …
Authors:
Clazinus Veijer, Marinus H. van Hulst, Benjamin Friedrichson, Maarten J. Postma, Antoinette D.I. van Asselt
Advancing measurement of children’s health-related quality of life - evidence from the QUOKKA (QUality OF Life in Kids: Key evidence to strengthen decisions in Australia) research program
Amid rising healthcare expenses, the importance of market transparency in medicine pricing takes center stage. This transparency influences the affordability and accessibility of medicines, posing a complex array of challenges and opportunities …
The use of disease or multi-use models (i.e. one model that can be used to determine the cost effectiveness of many new technologies in a certain disease) is increasingly being advocated [ 1 – 3 ]. Diabetes is a disease area where such models are …
Authors:
Mirre Scholte, Bram Ramaekers, Evangelos Danopoulos, Sabine E. Grimm, Andrea Fernandez Coves, Xiaoyu Tian, Thomas Debray, Jiongyu Chen, Lisa Stirk, Rachel Croft, Manuela Joore, Nigel Armstrong
Oncological treatments, traditionally based on pathologic classification and organ of origin, are increasingly shifting towards histology-independent targeted therapies, classified based on specific genomic or molecular alterations. This is based …
Authors:
Bradley M. Sugden, Sabine E. Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten, Teebah Abu-Zahra, Mark Perry, Mubarak Patel, Jiongyu Chen, Caro Noake, Manuela Joore, Willem J. A. Witlox
Sickle cell disease (SCD) refers to a heterogeneous group of genetic abnormalities affecting hemoglobin, the oxygen-carrying protein in red blood cells (RBCs) [ 1 ]. The sickled RBCs characteristic of SCD are more rigid and adherent and have a …
Authors:
William L. Herring, Meghan E. Gallagher, Nirmish Shah, KC Morse, Deirdre Mladsi, Olivia M. Dong, Anjulika Chawla, Jennifer W. Leiding, Lixin Zhang, Clark Paramore, Biree Andemariam
Cost-effectiveness analyses commonly use population or sample averages, which can mask key differences across subgroups and may lead to suboptimal resource allocation. Despite there being several new methods developed over the last decade, there …
Authors:
Gemma E. Shields, Paul Clarkson, Ash Bullement, Warren Stevens, Mark Wilberforce, Tracey Farragher, Arpana Verma, Linda M. Davies
The term orphan drug is recommended by the International Society for Pharmacoeconomics and Outcomes Research when a drug is indicated for the treatment of rare diseases with a prevalence threshold of 40–50 patients per 100,000 people [ 2 ]. The US …
Authors:
Tobias Sydendal Grand, Shijie Ren, James Hall, Daniel Oudin Åström, Stephane Regnier, Praveen Thokala
Open Access
13-04-2024 | Original Research Article
Health care policy makers in many jurisdictions use health economic decision models as a basis for information regarding the cost effectiveness of medicines and other health care interventions. Such information serves to inform policy decisions …
Authors:
Junfeng Wang, Xavier Pouwels, Bram Ramaekers, Geert Frederix, Chris van Lieshout, Rudolf Hoogenveen, Xinyu Li, G. Ardine de Wit, Manuela Joore, Hendrik Koffijberg, Anoukh van Giessen, Saskia Knies, Talitha Feenstra, the Dutch multi-use disease modeling consortium
Health technology assessment (HTA) aims to systematically assess the effectiveness and costs of interventions that are being considered for reimbursement within healthcare systems [ 1 – 5 ]. Generally, these assessments are supported by health …
Authors:
Yanara Marks, Jeffrey S. Hoch, Anna Heath, Petros Pechlivanoglou
Colorectal cancer (CRC) is the third most diagnosed malignancy and a leading cause of cancer deaths, accounting for an estimated 1.85 million new cases annually worldwide [ 1 ] and more than 4200 new cases annually in Norway [ 2 ]. The majority of …
Authors:
Anna Kenseth, Dominika Kantorova, Mikyung Kelly Seo, Eline Aas, John Cairns, David Kerr, Hanne Askautrud, Jørn Evert Jacobsen
Open Access
03-04-2024 | Overweight | Original Research Article
Childhood excess weight, a collective term for childhood overweight and obesity, remains a significant public health concern in many countries due to its association with overweight and obesity in adulthood and premature mortality [ 1 ]. Globally …
Authors:
Olu Onyimadu, Nerys M. Astbury, Felix Achana, Stavros Petrou, Mara Violato
Open Access
29-03-2024 | Original Research Article
Health state utility values (HSUVs), also referred to as “health utilities“, “utility weights”, “utility values” or “preference-based health-related quality of life measures”, are essential quantitative metrics signifying the cardinal strength of …
Authors:
Muchandifunga Trust Muchadeyi, Karla Hernandez-Villafuerte, Gian Luca Di Tanna, Rachel D. Eckford, Yan Feng, Michela Meregaglia, Tessa Peasgood, Stavros Petrou, Jasper Ubels, Michael Schlander
Open Access
26-03-2024 | Original Research Article
Economic evaluations of digital health interventions (DHIs) have increased in recent decades following the widespread development and uptake of DHIs. It is challenging to apply the standard methods of cost and effect estimation on DHIs since these …
Authors:
Zareen Abbas Khan, Kristian Kidholm, Sindre Andre Pedersen, Silje Marie Haga, Filip Drozd, Thea Sundrehagen, Ellen Olavesen, Vidar Halsteinli
Rachel O’Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin, Kim Dalziel, in collaboration with the Quality Of Life in Kids: Key evidence to strengthen decisions in Australia (QUOKKA) Project Team
